(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.92%
Live Chart Being Loaded With Signals
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system...
Stats | |
---|---|
今日成交量 | 116 465 |
平均成交量 | 417 803 |
市值 | 3.76M |
EPS | $0 ( 2024-04-03 ) |
下一个收益日期 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.160 |
ATR14 | $0.00400 (0.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Kontulis Caitlin | Sell | 335 | Common stock, $0.0001 par value |
2024-02-26 | Bitterman Robert J | Buy | 2 500 | Common stock, $0.0001 par value |
2024-02-20 | Bitterman Robert J | Sell | 1 804 | Common stock, $0.0001 par value |
2024-02-15 | Kontulis Caitlin | Sell | 658 | Common stock, $0.0001 par value |
2024-02-17 | Kontulis Caitlin | Sell | 523 | Common stock, $0.0001 par value |
INSIDER POWER |
---|
76.83 |
Last 97 transactions |
Buy: 3 139 429 | Sell: 140 691 |
音量 相关性
Phio Pharmaceuticals Corp 相关性 - 货币/商品
Phio Pharmaceuticals Corp 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-184 000 (0.00 %) |
EPS: | $-5.20 |
FY | 2023 |
营收: | $0 |
毛利润: | $-184 000 (0.00 %) |
EPS: | $-5.20 |
FY | 2022 |
营收: | $0 |
毛利润: | $-193 000 (0.00 %) |
EPS: | $-9.95 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-12.43 |
Financial Reports:
No articles found.
Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。